Cite
HARVARD Citation
Masters, J. et al. (2022). Model‐informed drug development supporting the approval of the avelumab flat‐dose regimen in patients with advanced renal cell carcinoma. CPT: pharmacometrics & systems pharmacology. pp. 458-468. [Online].